General Session XVIII: Hot Topics 2: Immunotherapy, Prevention and Pathology
Track
:
General Session
Program Code:
240
Date:
Saturday, November 15, 2008
Time:
10:45 AM to 12:00 PM
EST
Duration:
555 Minutes
Location:
Grand Ballroom 1/II
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Karen Kelly, M.D., University of Kansas Medical Center, Kansas City, Kan.
Karen Kelly, MD, is Deputy Director, Associate Director of Clinical Research, and the Frank B. Tyler Professor at The University of Kansas Cancer Center and School of Medicine in Kansas City.
After earning her medical degree at The University of Kansas School of Medicine, Dr Kelly completed her residency and her oncology fellowship at the University of Colorado Health Sciences Center. She built an academic career in thoracic oncology at the University of Colorado, where she was a faculty member for 16 years before leaving to accept her current position.
As Principal and Co-Principal Investigator, Dr Kelly has participated in the development of numerous clinical trials evaluating anticancer agents, primarily for small cell and nonƒ{small cell lung cancer. She has authored and coauthored nearly 100 publications, including original papers, abstracts, books, and book chapters. The results of her extensive research in lung cancer have appeared in several prominent oncology journals such as, the Journal of Clinical Oncology, Clinical Cancer Research, and Lung Cancer.
Dr Kelly is an active member of many professional organizations, including the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. In addition, she serves as Vice Chair of the Southwest Oncology Group Lung Committee.
James Mulshine, M.D., Associate Provost for Research, Rush Medical College
Dr. James L. Mulshine, MD, is the Vice President and Associate Provost of Research at Rush University Medical Center in Chicago, Illinois. Dr. Mulshine previously at the National Cancer Institute (NCI) where he was on the research faculty since 1983. While at the NCI, he served as head of the Intervention Section, chair of the lung cancer and chemoprevention faculty and chair of the Institutional Review Board. He was also the NCI representative to the Technology Transfer Review subcommittee for the director of the National Institutes of Health.
Dr. Mulshine is the primary academic officer responsible managing research activities at Rush University Medical School. Internationally recognized as an expert on lung cancer, At Rush, Dr. Mulshine’s research will concentrate on management of early diseases as a key to success in improving outcomes with lung cancer. He has been awarded eight patents and has over 250 scientific and medical publications. Dr. Mulshine received his BA from the College of the Holy Cross, and his medical degree from Loyola University Chicago’s Stritch School of Medicine. He completed his residency in internal medicine at the Cleveland Clinic Foundation, and moved to the NCI in 1980 where he completed clinical and research fellowships in medical oncology and then joined the faculty. Committed to continuing medical education, Dr. Mulshine is on numerous editorial boards and sits on national and international scientific and foundation advisory boards. He is a member of the American Society of Clinical Oncology; American Association of Cancer Research, and International Association for the Study of Lung Cancer .